Evotec, Halozyme

Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to enhance its capabilities
JPMorgan thinks may take time for market to digest Halozyme bid for Evotec
After Halozyme Therapeutics (HALO) confirmed it has submitted a non-binding proposal to the boards of Evotec (EVO) to acquire Evotec for EUR
Evotec surges on Halozyme takeover interest
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German biotech for €11.00 per share in cash, or about €2bn.
Evotec jumps as Halozyme confirms takeover interest (updated)
Evotec stock surges 10% as Halozyme Therapeutics expresses takeover interest, sparking investor excitement and speculation in the market.
Halozyme interested in acquiring Evotec for $2.1B, Bloomberg says
Evotec (EVO) is attracting potential takeover interest from Halozyme Therapeutics (HALO), Eyk Henning of Bloomberg reports, citing people
Halozyme Therapeutics Bids to Acquire German Competitor Evotec
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share,
Halozyme makes 2 billion euro buyout offer for drug developer Evotec
Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio. Halozyme intends to purchase all the shares of Evotec at 11 euros per share,
Germany’s Evotec Gets Takeover Interest From Halozyme
Germany’s Evotec SE is attracting potential takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc., people familiar with the matter said.
Halozyme Submits $2.11 Billion Acquisition Offer For Evotec
Halozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's management and supervisory board to buy the company for 11 euros a share in cash,
FierceBiotech11h
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an ...
MarketWatch8h
Evotec Shares Surge on $2.11 Billion Buyout Offer
Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...
ENDPOINTS NEWS5h
Evotec gains on Halozyme's takeover pro­pos­al
Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...
FierceBiotech4d
Evotec, after stock-tanking blows, attracts private equity buyout interest: report
Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall ...
Warburg Research Sticks to Their Buy Rating for Evotec (0IRF)
Warburg Research analyst Christian Ehmann maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of ...
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...